Brazil Advances Toward A Malaria Vaccine
Human trials begin for a Brazilian vaccine candidate with potential benefits for the Amazon and beyond
Paulo Pinto/Agência Brasil
The Brazilian Health Regulatory Agency (Anvisa) has authorized human trials of Vivaxin, a vaccine candidate designed to protect against malaria caused by *Plasmodium vivax*. Developed using entirely Brazilian technology, the research is led by the Vaccine Technology Center at the Federal University of Minas Gerais (UFMG).
🔒
This article is for premium readers only.
Support quality publishing and gain unrestricted access to our full library.
Sign in / Up to your Account:
📰 Continue Reading:
Share this exclusive article:
Filed under: news | DonateToRead